Removal Of ‘Legal’ And ‘Implicit’ Terms Cleared Way For ICH Q12 Guideline
Executive Summary
Concerns about potential regional variation and ambiguous applicability subside with final revision of lifecycle management guideline; training preparations begin.
You may also be interested in...
Woodcock: The US FDA Sets The Stage For Global Quality Dossiers
New approach could eliminate minor differences among authorities, enabling pharmaceutical manufacturing processes to become truly global.
Differences Put Aside As ICH Finalizes Guide On Post Approval Changes
An international guideline on managing post approval changes to drugs, which was initially criticized because of its incompatibility with legal frameworks in certain ICH regions such as the EU, has been finalized.
EMA Fee Revisions Expected To Resolve EC's Objections To ICH Q12 Guideline
Reducing dependence on Type II variation fees would free lifecycle management guideline from European Commission’s legal concerns.